Last updated: 11/03/2018 07:42:24
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An open-label phase II study of weekly intravenous Hycamtin and carboplatin as first-line treatment of chemonaive subjects with Extensive Disease Small Cell lung Cancer
Trial description: This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Overall response rate, as determined by radiologic evaluation (utilizing the World Health Organization [WHO] criteria), calculated as the number of participants with the indicated response
Timeframe: Baseline until up to Day 169
Secondary outcomes:
Time to response
Timeframe: From start of treatment to evidence of partial or complete response
Response duration
Timeframe: From time of partial or complete response to disease progression/death
Time to progression
Timeframe: From start of treatment to disease progression/death
Overall survival, calculated as the number of subjects who died from the start of treatment until follow-up
Timeframe: Week 1 up to maximum of Day 519
Grade 1 (mild) hematological toxicities
Timeframe: Week 1 through Endpoint (variable based on disease progression or toxicity)
Grade 2 (moderate) hematological toxicities
Timeframe: Week 1 through Endpoint (variable based on disease progression or toxicity
Grade 3 (severe) hematological toxicities
Timeframe: Week 1 through Endpoint (variable based on disease progression or toxicity
Grade 4 (life-threatening or disabling) hematological toxicities
Timeframe: Week 1 through Endpoint (variable based on disease progression or toxicity
Interventions:
Enrollment:
33
Primary completion date:
2008-01-05
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Lung Cancer, Small Cell
Product
topotecan
Collaborators
Not applicable
Study date(s)
June 2005 to May 2008
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Inclusion criteria:
- Adequate contraception methods include: systemic contraceptives or IUD for 3 months prior to start of the study medication or diaphragm plus spermicide; for males, condom plus spermicide; or total abstinence from sexual intercourse during the course of the study
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion criteria:
- Adequate contraception methods include: systemic contraceptives or IUD for 3 months prior to start of the study medication or diaphragm plus spermicide; for males, condom plus spermicide; or total abstinence from sexual intercourse during the course of the study
- Women of childbearing potential and sexually active males must practice or use an accepted and effective form of contraception
- Subjects who present with CNS metastases are eligible, provided the attending physician ascertains that the metastases are controlled before the start of chemotherapy, and the subject is asymptomatic on neurologic exam and is not receiving corticosteroid therapy to control symptoms. Continued use of other anti-seizure medication is permitted
- Free of active infection
- At screening, a probable life expectancy of at least 3 months
- No prior chemotherapy for SCLC or any chemotherapy within 5 years of the diagnosis of SCLC. Prior radiation to any symptomatic site is permitted provided that the indicator lesion site(s) are not irradiated, and radiation is completed before chemotherapy is started
- Performance status ECOG 0-1
- Renal: Serum Creatinine ≤1.5mg/dL (133mol/L) and CrCl 60 ml/min (Cockroft-Gault) [Cockroft, 1976] CrCl may be calculated using the Cockcroft-Gault formula: CrCl (ml/min) = Q x (140-age [yr]) x body wt [kg] 72 x serum creatinine [mg/dl] Q = 0.85 for females Q = 1.0 for males CrCl (ml/min) = K x (140-age [yr]) x body wt [kg] Serum creatinine [mol/L] K = 1.0 for females K = 1.23 for males
- Hepatic: Serum bilirubin (1.5 mg/dL), SGOT (AST), SGPT (ALT) and Alkaline Phosphatase 2 times the upper limit of normal (ULN) if liver metastases are absent by abdominal CT or MRI, or 5 times ULN if liver metastases are present
- At least 18 years old
- Written informed consent (subject's written understanding of and agreement to participate in this study.
- Subject with histologically-confirmed extensive small cell lung cancer or unequivocally positive positive cytological evidence (sputum, at least two, or aspirate biopsy)
- Presence of measurable disease according to World Health Organization (WHO)* criteria, as determined by diagnostic tests, including CT scan of the chest and abdomen, or MRI scan of the brain, or CXR, or PET CT, MRI, and/or CXR are the preferred diagnostic methods to evaluate disease during the course of this study. Use of positron-emission tomography (PET) is not required, but is permitted if it is the standard diagnostic tool employed by the institution. Measurable disease
- Measurable disease, either on CT or MRI scan, requires one diameter 1 cm and one diameter 2 cm.
- Measurable disease on CXR requires both diameters 2 cm.
- Palpable tumor masses that could not be evaluated radiologically require two diameters 2 cm
- At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the subject).
- Subjects with central nervous system metastases are eligible as long as the attending doctor determines that the metastases are under control before the start of chemotherapy, and the subject has no symptoms of spreading of disease to the brain, and is not receiving drugs called steroids to control the symptoms.
- Laboratory criteria: Subjects must have adequate bone marrow reserve and adequate kidney and liver function. Exclusion criteria:
- Concurrent or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of SCLC. (Concurrent radiation for palliation of bone metastases and CNS lesions must be discussed with and approved by the GlaxoSmithKline Medical Monitor)
- Concurrent severe medical problems other than the diagnosis of SCLC, which would significantly limit full compliance with the study or expose the patient to extreme risk
- Concomitant malignancies or previous malignancies other than SCLC within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or localized low grade prostate cancer (contact GlaxoSmithKline Medical Monitor to discuss enrolment of subjects with low grade prostate cancer)
- Present clinical signs or symptoms of brain and/or leptomeningeal metastases confirmed by CT or MRI brain scan, or corticosteroid treatment to control symptoms of brain metastases
- Uncontrolled infection
- Ongoing tumor or previous tumor other than lung cancer within the last 5 years.
- Symptoms of spreading of the disease to the brain that requires treatment with drugs called steroids
- Severe medical problems other than the diagnosis of SCLC that would limit the ability of the subject to follow study plan or that would expose the subject to extreme risk.
- Ongoing or planned chemotherapy, immunotherapy, radiation treatment, or other experimental drug therapy for the treatment of SCLC.
- Use of investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication
- Women who are pregnant or lactating.
- Women who can become pregnant who refuse to practice an adequate form of birth control.
- Subjects with history of allergic reaction to chemicals related to HYCAMTIN and PARAPLATIN.
- Subjects with pre-existing heart disease, such as congestive heart failure, irregular heartbeats that require treatment, and heart attack within the last 3-months.
Adequate hematologic, renal and hepatic function •Hematologic: ANC 1500/mm3 [1.5 x 109/L], platelet count 100,000/L (100 x 109/L), hemoglobin 9.0 g/dL
Presence of at least one bidimensionally measurable, non-CNS lesion (indicator lesion). If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology
Trial location(s)
Location
GSK Investigational Site
Richmond, Virginia, United States, 23230
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63141
Status
Study Complete
Location
GSK Investigational Site
Metairie, Louisiana, United States, 70006
Status
Study Complete
Location
GSK Investigational Site
Concord, California, United States, 94520
Status
Terminated/Withdrawn
Showing 1 - 6 of 13 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2008-01-05
Actual study completion date
2008-01-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website